Baseline Clinical and Pet-Ct Tumor Burden Parameters Do Not Predict Outcome of Relapse/Refractory Aggressive B Cell Lymphoma Patients Treated With Anti-Cd19 Car T-Cells

Hematological Oncology - United Kingdom
doi 10.1002/hon.188_2631

Related search